Cargando…
YKL-40 as a Potential Biomarker for the Differential Diagnosis of Alzheimer’s Disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, associated with extensive neuronal loss, dendritic and synaptic changes resulting in significant cognitive impairment. An increased number of studies have given rise to the neuroinflammatory hypothesis in AD. It is widely accepted...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777884/ https://www.ncbi.nlm.nih.gov/pubmed/35056368 http://dx.doi.org/10.3390/medicina58010060 |
_version_ | 1784637179722465280 |
---|---|
author | Mavroudis, Ioannis Chowdhury, Rumana Petridis, Foivos Karantali, Eleni Chatzikonstantinou, Symela Balmus, Ioana Miruna Luca, Iuliana Simona Ciobica, Alin Kazis, Dimitrios |
author_facet | Mavroudis, Ioannis Chowdhury, Rumana Petridis, Foivos Karantali, Eleni Chatzikonstantinou, Symela Balmus, Ioana Miruna Luca, Iuliana Simona Ciobica, Alin Kazis, Dimitrios |
author_sort | Mavroudis, Ioannis |
collection | PubMed |
description | Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, associated with extensive neuronal loss, dendritic and synaptic changes resulting in significant cognitive impairment. An increased number of studies have given rise to the neuroinflammatory hypothesis in AD. It is widely accepted that AD brains show chronic inflammation, probably triggered by the presence of insoluble amyloid beta deposits and neurofibrillary tangles (NFT) and is also related to the activation of neuronal death cascade. In the present study we aimed to investigate the role of YKL-40 levels in the cerebrospinal fluid (CSF) in the diagnosis of AD, and to discuss whether there are further potential roles of this protein in the management and treatment of AD. We conducted an online search on PubMed, Web of Science, and the Cochrane library databases from 1990 to 2021. The quantitative analysis showed that the levels of YKL-40 were significantly higher in Alzheimer’s disease compared to controls, to mild cognitive impairment (MCI) AD (MCI-AD) and to stable MCI. They were also increased in MCI-AD compared to stable MCI. The present study shows that the CSF levels of YKL-40 could be potentially used as a biomarker for the prognosis of mild cognitive impairment and the likelihood of progression to AD, as well as for the differential diagnosis between AD and MCI. |
format | Online Article Text |
id | pubmed-8777884 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87778842022-01-22 YKL-40 as a Potential Biomarker for the Differential Diagnosis of Alzheimer’s Disease Mavroudis, Ioannis Chowdhury, Rumana Petridis, Foivos Karantali, Eleni Chatzikonstantinou, Symela Balmus, Ioana Miruna Luca, Iuliana Simona Ciobica, Alin Kazis, Dimitrios Medicina (Kaunas) Review Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, associated with extensive neuronal loss, dendritic and synaptic changes resulting in significant cognitive impairment. An increased number of studies have given rise to the neuroinflammatory hypothesis in AD. It is widely accepted that AD brains show chronic inflammation, probably triggered by the presence of insoluble amyloid beta deposits and neurofibrillary tangles (NFT) and is also related to the activation of neuronal death cascade. In the present study we aimed to investigate the role of YKL-40 levels in the cerebrospinal fluid (CSF) in the diagnosis of AD, and to discuss whether there are further potential roles of this protein in the management and treatment of AD. We conducted an online search on PubMed, Web of Science, and the Cochrane library databases from 1990 to 2021. The quantitative analysis showed that the levels of YKL-40 were significantly higher in Alzheimer’s disease compared to controls, to mild cognitive impairment (MCI) AD (MCI-AD) and to stable MCI. They were also increased in MCI-AD compared to stable MCI. The present study shows that the CSF levels of YKL-40 could be potentially used as a biomarker for the prognosis of mild cognitive impairment and the likelihood of progression to AD, as well as for the differential diagnosis between AD and MCI. MDPI 2021-12-30 /pmc/articles/PMC8777884/ /pubmed/35056368 http://dx.doi.org/10.3390/medicina58010060 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Mavroudis, Ioannis Chowdhury, Rumana Petridis, Foivos Karantali, Eleni Chatzikonstantinou, Symela Balmus, Ioana Miruna Luca, Iuliana Simona Ciobica, Alin Kazis, Dimitrios YKL-40 as a Potential Biomarker for the Differential Diagnosis of Alzheimer’s Disease |
title | YKL-40 as a Potential Biomarker for the Differential Diagnosis of Alzheimer’s Disease |
title_full | YKL-40 as a Potential Biomarker for the Differential Diagnosis of Alzheimer’s Disease |
title_fullStr | YKL-40 as a Potential Biomarker for the Differential Diagnosis of Alzheimer’s Disease |
title_full_unstemmed | YKL-40 as a Potential Biomarker for the Differential Diagnosis of Alzheimer’s Disease |
title_short | YKL-40 as a Potential Biomarker for the Differential Diagnosis of Alzheimer’s Disease |
title_sort | ykl-40 as a potential biomarker for the differential diagnosis of alzheimer’s disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777884/ https://www.ncbi.nlm.nih.gov/pubmed/35056368 http://dx.doi.org/10.3390/medicina58010060 |
work_keys_str_mv | AT mavroudisioannis ykl40asapotentialbiomarkerforthedifferentialdiagnosisofalzheimersdisease AT chowdhuryrumana ykl40asapotentialbiomarkerforthedifferentialdiagnosisofalzheimersdisease AT petridisfoivos ykl40asapotentialbiomarkerforthedifferentialdiagnosisofalzheimersdisease AT karantalieleni ykl40asapotentialbiomarkerforthedifferentialdiagnosisofalzheimersdisease AT chatzikonstantinousymela ykl40asapotentialbiomarkerforthedifferentialdiagnosisofalzheimersdisease AT balmusioanamiruna ykl40asapotentialbiomarkerforthedifferentialdiagnosisofalzheimersdisease AT lucaiulianasimona ykl40asapotentialbiomarkerforthedifferentialdiagnosisofalzheimersdisease AT ciobicaalin ykl40asapotentialbiomarkerforthedifferentialdiagnosisofalzheimersdisease AT kazisdimitrios ykl40asapotentialbiomarkerforthedifferentialdiagnosisofalzheimersdisease |